Intratumoral Cancer Therapies Market Size was approximately USD 93 million in 2021

The Intratumoral Cancer Therapies market is expected to grow in the upcoming years owing to the potential entry of Intratumoral emerging therapies and their readily uptake.

The Intratumoral Cancer Therapies market report provides current treatment practices, emerging drugs, Intratumoral Cancer Therapies market share of the individual therapies, current and forecasted Intratumoral Cancer Therapies market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Intratumoral Cancer Therapies treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Intratumoral Cancer Therapies market.

Key takeaways from the Intratumoral Cancer Therapies Market Research Report

• As per DelveInsight's estimates, the total NMSC incident cases in the 7MM was 774,926 in 2020.

• In 2021, the total Intratumoral Cancer patient pool cases across 7MM were about 469 K which are expected to grow during the study period, i.e., 2019-2032.

• Intratumoral Cancer Therapies market companies are working in the market include Checkmate Pharmaceuticals, OncoSec Medical Incorporated, Merck, Istari Oncology, Replimune/ Regeneron, Philogen, Exicure, Sirnaomics, Nanobiotix, Intensity Therapeutics, NanOlogy, Lokon Pharma, DNAtrix, Treovir, Idera Pharmaceuticals, Immunovative Therapies, among others.

• The Intratumoral Cancer pipeline therapies expected to get launched include Vidutolimod, TAVO, CAVATAK, PVSRIPO, RP1, Daromun, Cavrotolimod, Cotsiranib, Hensify, INT230-6, Delolimogene mupadenorepvec, Intuvax, Tasadenoturev, G207, Tilsotolimod, AlloStim, and others.

Explore more information of Intratumoral Cancer Therapies Market Research Report and Get a snapshot of the Intratumoral Cancer Therapy Market Size @ https://www.delveinsight.com/sample-request/intratumoral-cancer-therapies-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Intratumoral Cancer Therapies Overview

Intratumoral cancer therapies by including details such as overview of Intratumoral Cancer Therapies, advantages, disadvantages and available therapies. Comprehensive epidemiology insight of the tumors targeted by Intratumoral Cancer Therapies. IT therapy refers to any therapy that is delivered in very close anatomical proximity to a tumor with the intention of direct uptake by tumors or tumor cells. It is a therapeutic strategy which aims to use the tumor as its own vaccine.

Intratumoral Cancer Therapies Epidemiology Segmentation in the 7MM

• Total Incident Cases of Selected Cancer Types (Melanoma, Nonmelanoma skin cancer, Head and Neck Cancer, Pancreatic Cancer, Renal Cell Carcinoma, Colorectal Cancer, Breast Cancer, Brain Cancer, and Soft Tissue Sarcoma)

• Target Patient Pool of Intratumoral Therapies by Cancer Types

• Treated Cases by Cancer Types

Understand how Intratumoral Cancer Therapies Epidemiology Segmentation Landscape and Intratumoral Cancer Therapies Epidemiology Report @ https://www.delveinsight.com/sample-request/intratumoral-cancer-therapies-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Intratumoral Cancer Therapy Market Outlook

Intratumoral (intralesional) administration of immunotherapeutics is a promising way to target local tumor immunity barriers directly. Different categories of Intratumoral Cancer Therapies in the pipeline under investigation include oncolytic viruses, monoclonal antibodies, and small molecules, and others are being investigated.

Intratumoral Cancer Therapy Market Landscape

The present Intratumoral Cancer Therapy market consists of only three approved therapies, i.e., Imlygic (Talimogene laherparepvec/T-VEC; Amgen), Delytact (teserpaturev/G47∆; Daiichi Sankyo) and Hensify (NBTXR3; Nanobiotix). The first approval for an intratumoral therapy was received in 2015, wherein the United States Food and Drug Administration (US FDA) approved Imlygic (talimogene laherparepvec; T-Vec) to treat melanoma. It is a genetically modified herpes simplex virus type 1-based oncolytic immunotherapy and is the first oncolytic virus approved by the US FDA to treat unresectable melanoma recurrent after the initial surgery. Later on in 2019, the European Union (EU) approved Hensify (NBTXR3) for the treatment of patients suffering from Soft tissue sarcoma, and recently in 2021, the Japan Ministry of Health, Labour and Welfare (MHLW) granted conditional and time-limited approval to Delytact (teserpaturev) for the treatment of malignant glioma.

To find the details of Intratumoral Cancer Therapy Market Drivers and Barriers of the report @ https://www.delveinsight.com/report-store/intratumoral-cancer-therapies-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Intratumoral Cancer Therapy Pipeline Therapies and Companies

• Vidutolimod (CMP-001): Checkmate Pharmaceuticals
• TAVO(tavokinogene telseplasmid): OncoSec Medical Incorporated
• CAVATAK (V937; CVA21): Merck & Co (Viralytics)
• PVSRIPO (PVS-RIPO): Istari Oncology
• RP1 (vusolimogene oderparepvec): Replimune/ Regeneron
• Daromun (Nidlegy): Philogen
• Cavrotolimod (AST-008): Exicure
• Cotsiranib (STP705): Sirnaomics
• Hensify (NBTXR3/ PEP503): Nanobiotix
• INT230-6 (Cisplatin/vinblastine): Intensity Therapeutics
• NanoPac (LSAM paclitaxel): NanOlogy
• Delolimogene mupadenorepvec (LOAd703): Lokon Pharma
• Intuvax (Ilixadencel)
• Tasadenoturev (DNX-2401): DNAtrix
• G207: Treovir
• Tilsotolimod (IMO-2125): Idera Pharmaceuticals
• AlloStim: Immunovative Therapies

Intratumoral Cancer Therapies Market Dynamics

DelveInsight's Intratumoral Cancer Therapies market analysis demonstrates that these therapies have immense potential to transform the treatment landscape by turning cold tumors into hot tumor and making their identification convenient by the immune system. However, the present understanding of Intratumoral therapies is poor and they also have faced backlash from the recent clinical trial failures at late stages; DelveInsight estimates that the future carries a promising outlook for the Intratumor Cancer Therapies market owing to potential emerging therapies, promising clinical trial results, the influx of pharma and biotech players, better R&D, and increasing healthcare expenditure.

Learn more about available Intratumoral Cancer Therapies Drug Pipeline Therapies @ https://www.delveinsight.com/report-store/intratumoral-cancer-therapies-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Intratumoral Cancer Therapies Market Report

• Coverage- 7MM

• Study Period- 2019-2032

• Intratumoral Cancer Therapies Companies- Checkmate Pharmaceuticals, OncoSec Medical Incorporated, Merck, Istari Oncology, Replimune/ Regeneron, Philogen, Exicure, Sirnaomics, Nanobiotix, Intensity Therapeutics, NanOlogy, Lokon Pharma, DNAtrix, Treovir, Idera Pharmaceuticals, Immunovative Therapies, among others.

• Intratumoral Cancer Therapies Pipeline Therapies- Vidutolimod, TAVO, CAVATAK, PVSRIPO, RP1, Daromun, Cavrotolimod, Cotsiranib, Hensify, INT230-6, Delolimogene mupadenorepvec, Intuvax, Tasadenoturev, G207, Tilsotolimod, AlloStim, and others.

• Intratumoral Cancer Therapies Market Dynamics: Intratumoral Cancer Therapies Market Drivers and Barriers

Table of Content

1. Key Insights
2. Report Introduction
3. Intratumoral cancer therapies Market Overview at a Glance
4. Key Highlights from Report
5. Executive Summary of Intratumoral cancer therapy
6. Epidemiology and Market Forecast Flow
7. Background and Overview
8. Epidemiology and Patient Population
9. Key Endpoints in Intratumoral Cancer Therapies
10. Intratumoral Cancer Therapies Marketed Therapies
11. Intratumoral Cancer Therapies Emerging Therapies
12. Attribute Analysis
13. Intratumoral Cancer Therapies: 7 Major Market Analysis
14. Market Access and Reimbursement
15. KOL Views
16. SWOT analysis
17. Unmet Needs
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Read more about the Intratumoral Cancer Therapies Market Landscape and Forecast @ https://www.delveinsight.com/report-store/intratumoral-cancer-therapies-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Know more about Healthcare Market Research Reports and Healthcare Research Reports @ https://www.delveinsight.com/?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.